CA
NZ
UK
AU
IND
US
● ADVANTIS, trading under the ticker ADVT, sits at the extreme micro end of the market, with a quoted share price measured in fractions of a cent and aMarket Valuereported at less than $100,000.
Aethlon Medical, Inc. (NASDAQ: AEMD), a micro-cap medical-device developer, drew attention after its shares slid in a single session, according to market-data feeds. The move landed as the company continues to push its lead Hemopurifier device through an early-stage oncology study and shore up …
● Abeona Therapeutics has completed one of the harder transitions in biotech: moving from a development-stage gene-therapy company to one with an approved product generating revenue.
Volatility is a familiar feature for small clinical-stage drug developers, and ABVC BioPharma, Inc. (NASDAQ: ABVC) is no exception. The Nasdaq-listed biopharmaceutical company, which is advancing a spread of mid-stage candidates across cancer, neuropsychiatry and blood disorders, has seen its shares swing sharply this …
Actuate Therapeutics, Inc (NASDAQ:ACTU) presents an unusually stark contrast: encouraging new cancer data on one side, a looming cash crunch on the other. Just as the clinical-stage biotech published fresh preclinical results supporting its lead drug elraglusib, its own filings warned that cash could …
A double-digit single-session gain in a stock as small as AccuStem Sciences Inc (OTC:ACUT) is easy to over-interpret. With aMarket Valueof only a few million dollars and a handful of employees, the shares can move sharply on very light volume.
Few recent stories in cell therapy have turned as sharply as Adaptimmune Therapeutics plc (OTC:ADAPY)'s. A company that in 2024 launched the first FDA-approved engineered T-cell receptor therapy for a solid tumor now trades for pennies on the over-the-counter market after a 2025 delisting …
Neogen (NASDAQ:NEOG) shares are trading sharply higher in pre-market trading, extending recent gains after strong institutional buying activity and improving analyst sentiment. Neogen is a global life sciences company dedicated to protecting the world's foodSupplyand improving animal health, operating through its Food Safety and …
A NASDAQ-listed clinical-stage oncology company is trading sharply lower in pre-market trading despite announcing positive updated Phase 1 data for its lead cancer therapy, a reaction that runs counter to what would typically be viewed as encouraging news. Pyxis Oncology (NASDAQ:PYXS) reported that MICVO …
Tyra Biosciences (NASDAQ:TYRA) shares are plunging over 21% in pre-market trading, giving back recent gains that had been tied to optimism around SURF302 trial data expectations in FGFR-driven cancers. Tyra Biosciences is a clinical-stage biopharmaceutical company focused on developing next-generation precision medicines targeting fibroblast …
Please wait processing your request...